BRPI0910513B8 - uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia - Google Patents

uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia

Info

Publication number
BRPI0910513B8
BRPI0910513B8 BRPI0910513A BRPI0910513A BRPI0910513B8 BR PI0910513 B8 BRPI0910513 B8 BR PI0910513B8 BR PI0910513 A BRPI0910513 A BR PI0910513A BR PI0910513 A BRPI0910513 A BR PI0910513A BR PI0910513 B8 BRPI0910513 B8 BR PI0910513B8
Authority
BR
Brazil
Prior art keywords
polypeptide
cancer
leukemia
breast cancer
immunity
Prior art date
Application number
BRPI0910513A
Other languages
English (en)
Inventor
Okano Fumiyoshi
Shimizu Masaki
Saito Takanori
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of BRPI0910513A2 publication Critical patent/BRPI0910513A2/pt
Publication of BRPI0910513B1 publication Critical patent/BRPI0910513B1/pt
Publication of BRPI0910513B8 publication Critical patent/BRPI0910513B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

usos de pelo menos um polipeptídeo, usos de pelo menos um vetor recombinante, célula apresentadora de antígeno isolada, célula t isolada, método para a indução de imunidade, métodos para a detecção de câncer e reagente para a detecção de câncer. um agente indutor de imunidade que compreende como ingrediente(s) eficaz(es) pelo menos um polipeptídeo selecionado a partir dos polipeptídeos a seguir, o(s) polipeptídeo(s) que possui(em) atividades/atividade indutora de imunidade, ou que possui(em) como ingrediente(s) eficaz(es) um vetor(es) recombinante(s) que compreende polinucleotídeo(s) que codificam o(s) polipeptídeo(s) e os que é/são capazes de expressar o(s) polipeptídeo(s) in vivo podem ser usados para terapia e/ou profilaxia de câncer: (a) um polipeptídeo que consiste, essencialmente, em pelo menos 7 aminoácidos consecutivos em qualquer uma das sequências de aminoácidos de números ímpares dentre as seq id n°s: 3 a 95 da listagem de sequência; (b) um polipeptídeo que apresenta identidade de sequência de pelo menos 90% com o polipeptídeo (a) que consiste, essencialmente, em pelo menos 7 aminoácidos; e (c) um polipeptídeo que compreende o polipeptídeo (a) ou (b) como uma sequência parcial do mesmo. ademais, já que os polipeptídeo(s) acima reagem com os anticorpos que existe especificamente no soro de um paciente com câncer, é possível detectar o câncer em um ser vivo através da medição dos anticorpos em uma amostra.
BRPI0910513A 2008-07-10 2009-07-10 uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia BRPI0910513B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008180548 2008-07-10
JP2008-180548 2008-07-10
PCT/JP2009/062574 WO2010005069A1 (ja) 2008-07-10 2009-07-10 免疫誘導剤及び癌の検出方法

Publications (3)

Publication Number Publication Date
BRPI0910513A2 BRPI0910513A2 (pt) 2015-09-29
BRPI0910513B1 BRPI0910513B1 (pt) 2020-06-16
BRPI0910513B8 true BRPI0910513B8 (pt) 2021-05-25

Family

ID=41507179

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910513A BRPI0910513B8 (pt) 2008-07-10 2009-07-10 uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia

Country Status (16)

Country Link
US (1) US8901082B2 (pt)
EP (1) EP2319533B1 (pt)
JP (1) JP5703562B2 (pt)
KR (1) KR101323192B1 (pt)
CN (1) CN102089001B (pt)
AU (1) AU2009270182B2 (pt)
BR (1) BRPI0910513B8 (pt)
CA (1) CA2730088C (pt)
DK (1) DK2319533T3 (pt)
ES (1) ES2633468T3 (pt)
HU (1) HUE035804T2 (pt)
MX (1) MX2011000116A (pt)
PL (1) PL2319533T3 (pt)
PT (1) PT2319533T (pt)
RU (1) RU2519675C2 (pt)
WO (1) WO2010005069A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305300B1 (en) * 2008-07-10 2016-04-06 Toray Industries, Inc. Pharmaceutical composition for treatment and prevention of cancer
WO2012074642A1 (en) 2010-10-28 2012-06-07 Shaw Industries Group, Inc. Methods and devices for controlling a tufting machine for forming tufted carpet
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
JP7087387B2 (ja) 2016-03-28 2022-06-21 東レ株式会社 免疫誘導剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU640397B2 (en) * 1989-08-25 1993-08-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
AU2001253282A1 (en) * 2000-04-07 2001-10-23 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
RU2311920C2 (ru) * 2000-09-20 2007-12-10 Корикса Корпорейшн Композиции и способы для лечения и диагностики рака легких
WO2003060080A2 (en) * 2001-12-21 2003-07-24 Idexx Laboratories, Inc. Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
AU2003272511A1 (en) * 2002-09-13 2004-04-30 Dyax Corporation Cd44-binding ligands
US20040253606A1 (en) * 2002-11-26 2004-12-16 Protein Design Labs, Inc. Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
WO2005083074A1 (ja) * 2004-03-01 2005-09-09 Kanazawa University Technology Licensing Organization Ltd. 腫瘍抗原ペプチド
JP4547197B2 (ja) * 2004-06-30 2010-09-22 公正 安元 癌特異的腫瘍抗原
WO2008034076A2 (en) * 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
US20100233167A1 (en) * 2007-05-10 2010-09-16 Ramesh Bhatt Chain reaction creating oligomers from repeat units of binding molecules

Also Published As

Publication number Publication date
CA2730088C (en) 2020-04-14
MX2011000116A (es) 2011-02-25
CN102089001B (zh) 2015-01-14
CA2730088A1 (en) 2010-01-14
WO2010005069A1 (ja) 2010-01-14
RU2011104704A (ru) 2012-08-20
EP2319533B1 (en) 2017-05-10
DK2319533T3 (en) 2017-07-17
ES2633468T3 (es) 2017-09-21
US8901082B2 (en) 2014-12-02
JP5703562B2 (ja) 2015-04-22
AU2009270182B2 (en) 2015-01-22
CN102089001A (zh) 2011-06-08
BRPI0910513A2 (pt) 2015-09-29
JPWO2010005069A1 (ja) 2012-01-05
EP2319533A1 (en) 2011-05-11
EP2319533A4 (en) 2012-11-07
PL2319533T3 (pl) 2017-10-31
US20110130343A1 (en) 2011-06-02
KR20110019766A (ko) 2011-02-28
HUE035804T2 (en) 2018-05-28
PT2319533T (pt) 2017-07-20
BRPI0910513B1 (pt) 2020-06-16
KR101323192B1 (ko) 2013-10-30
RU2519675C2 (ru) 2014-06-20
AU2009270182A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
ES2661500T3 (es) Variantes de HMGB1 y sus usos
BR112016002753A2 (pt) anticorpos contra o inibidor-1 de ativador de plasminogênio (pai-1) e usos dos mesmos
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
RU2008137635A (ru) Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
NZ598348A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
BR112012032708A2 (pt) proteína de fusão anticâncer.
JP2014122214A5 (pt)
DK1548032T3 (da) KDR-peptider og vacciner indeholdende disse
RU2019124678A (ru) Слитый белок pd1-41bbl и способы его применения
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
NZ708990A (en) Method for activating helper t cell
MX358772B (es) Metodo para detectar cancer.
PH12015500461A1 (en) Novel il-17a binding molecules and medical uses thereof
BRPI0910513B8 (pt) uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia
Ueda et al. Induction of autophagic cell death of glioma-initiating cells by cell-penetrating D-isomer peptides consisting of Pas and the p53 C-terminus
ATE509096T1 (de) Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält
WO2013177593A2 (en) Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
WO2013072901A2 (en) Compositions and methods for treating glioma
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
FI3380115T3 (fi) Peptidejä piwil1:stä
BR112017022205A2 (pt) anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada
IN2014DN09963A (pt)
BR112016014072A2 (pt) anticorpo isolado, sintético ou recombinante humano, ou uma parte funcional ou um equivalente funcional do mesmo, molécula de ácido nucleico isolado, sintético ou recombinante, vetor, célula isolada ou recombinante ou um animal não humano, composição, uso de um anticorpo ou parte funcional ou equivalente funcional, e, métodos para produzir um anticorpo ou parte funcional ou equivalente funcional, para detectar células mieloproliferativas ou linfoproliferativas, para determinar se uma célula mieloide ou célula linfoide é uma célula mieloproliferativa ou célula linfoproliferativa, para identificar células mieloproliferativas ou linfoproliferativas, para determinar se células mieloproliferativas ou linfoproliferativas estão presentes em uma amostra, para tratar e/ou prevenir um distúrbio mieloproliferativo ou linfoproliferativo, para determinar se um indivíduo sofre de um distúrbio mieloproliferativo ou linfoproliferativo, para tipificar uma amostra contendo célula mieloide ou uma amostra contendo célula linfoide de um indivíduo, e, para determinar se um paciente que sofre de um distúrbio mieloproliferativo ou distúrbio linfoproliferativo é um candidato para o tratamento com um anticorpo
MX2023003371A (es) Receptores de células t específicos de mage-a3 y su uso.
BR112016016917A2 (pt) Sistema de administração de fármaco

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/06/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF